These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 20071795)
1. Phase 0 (zero) clinical trials: a myth or reality? Jain A Indian J Cancer; 2010; 47(1):70. PubMed ID: 20071795 [No Abstract] [Full Text] [Related]
2. [Recent proposals for early stage clinical trials of cancer]. Ohashi Y Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():292-4. PubMed ID: 7986106 [TBL] [Abstract][Full Text] [Related]
3. Clinical drug trials. Edgar L Can Nurse; 1983 Feb; 79(2):24-5. PubMed ID: 6549907 [No Abstract] [Full Text] [Related]
4. [Current status and issues in clinical trials of anticancer agents]. Kojima H Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():295-301. PubMed ID: 7986107 [TBL] [Abstract][Full Text] [Related]
6. [The revision of Guidelines for Clinical Evaluation Methods of Anti-Cancer Drugs in Japan]. Andoh M; Fujiwara Y; Shimada Y Gan To Kagaku Ryoho; 2006 Jul; 33(7):1015-9. PubMed ID: 16878363 [TBL] [Abstract][Full Text] [Related]
7. Adaptive design may hasten clinical trials. Schmidt C J Natl Cancer Inst; 2007 Jan; 99(2):108-9. PubMed ID: 17227993 [No Abstract] [Full Text] [Related]
8. Clinical cancer research 2001: new agents and therapies. Verweij J; de Vries EG Drug Resist Updat; 2001 Aug; 4(4):217-23. PubMed ID: 11991676 [No Abstract] [Full Text] [Related]
9. Phase 0 clinical trials in oncology: a paradigm shift for early drug development? Takimoto CH Cancer Chemother Pharmacol; 2009 Mar; 63(4):703-9. PubMed ID: 18615251 [TBL] [Abstract][Full Text] [Related]
10. [Methodological features of assessing the effectiveness of adjuvant therapy in clinical trials]. Dvoĭrin VV Vopr Onkol; 1986; 32(6):18-22. PubMed ID: 3523991 [No Abstract] [Full Text] [Related]
11. Trend toward noninferiority trials may mean more difficult interpretation of trial results. Tuma RS J Natl Cancer Inst; 2007 Dec; 99(23):1746-8. PubMed ID: 18042926 [No Abstract] [Full Text] [Related]
12. Proposal to rigorously evaluate the clinical benefits associated with a novel anti-neoplastic strategy outside the confines of a randomized trial. Markman M Oncology; 2010; 79(5-6):321-3. PubMed ID: 21430398 [No Abstract] [Full Text] [Related]
13. Phase 0 (zero) clinical trials: more than zero benefit? Schellens JH Eur J Cancer; 2009 Mar; 45(5):728-9. PubMed ID: 19231159 [No Abstract] [Full Text] [Related]
14. Phase II clinical trials. Carter SK; Selawry O Natl Cancer Inst Monogr; 1977 Mar; (45):81-92. PubMed ID: 337157 [No Abstract] [Full Text] [Related]
15. Clinical development of temsirolimus, a novel mTOR inhibitor, for treatment of advanced malignancies. Dancey JE Semin Oncol; 2009 Dec; 36 Suppl 3():S1-2. PubMed ID: 19963095 [No Abstract] [Full Text] [Related]
16. Advances and challenges in the use of biomarkers in clinical trials. Chabner B Clin Adv Hematol Oncol; 2008 Jan; 6(1):42-3. PubMed ID: 18322440 [No Abstract] [Full Text] [Related]